Loading clinical trials...
Loading clinical trials...
Ruxolitinib and Methylprednisolone As First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Conditions
Interventions
Ruxolitinib Oral Tablet
Methylprednisolone
Locations
1
China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Start Date
November 1, 2018
Primary Completion Date
September 20, 2024
Completion Date
September 20, 2024
Last Updated
October 1, 2024
NCT02611180
NCT04645667
NCT02806947
NCT01530256
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions